Table 2

Baseline population characteristics of 378 patients with raised blood biomarker result undergoing TE

VariableAll patients undergoing TE (n=378)Hazardous alcohol use* (n=174)Type 2 diabetes* (n=211)Raised ALT* (any case) (n=54)
Age, years61.8 (15.0)54.8 (14.9)68.5 (11.3)57.0 (11.5)
Male, n (%)255 (67.5)138 (79.3)130 (61.6)32 (59.3)
Body mass index, kg/m228.53 (5.25)26.5 (4.2)30.0 (5.2)31.1 (5.7)
Obesity, n (%)130 (34.4)32 (18.4)100 (47.4)29 (53.7)
Hypertension, n (%)173 (45.8)47 (27.0)134 (63.5)23 (42.6)
Metabolic syndrome, n (%)117 (31.0)18 (10.3)105 (49.8)24 (44.4)
Ischaemic heart disease, n (%)53 (14.0)11 (6.3)44 (20.9)7 (13.0)
Type 2 diabetes, n (%)211 (55.8)20 (5.7)211 (100)27 (50.0)
Hazardous alcohol use, n (%)174 (46.0)174 (100)20 (9.5)18 (33.3)
Platelets, 109/L240.66 (62.45)240.2 (54.8)239.6 (65.0)240.2 (64.6)
Creatinine, µmol/L90.21 (23.65)87.7 (20.8)92.9 (27.9)85.2 (15.0)
Bilirubin, µmol/L11.97 (5.04)12.4 (4.4)11.7 (5.3)11.2 (6.2)
Albumin, g/L37.78 (2.92)38.2 (2.9)37.5 (3.0)38.0 (2.8)
ALT, IU/L28.09 (19.06)28.4 (21.4)27.2 (15.7)60.4 (30.6)
AST, IU/L27.91 (18.97)30.7 (24.6)25.0 (11.0)52.0 (39.6)
AST:ALT ratio1.09 (0.36)1.16 (0.35)1.03 (0.37)0.86 (0.24)
  • Numerical variables are displayed as mean (SD), categorical variables are displayed as n (%).

  • *Patient numbers refer to patients fulfilling the single risk factor alone (see figure 2).

  • ALT, alanine aminotransferase, AST, aspartate aminotransferase; TE, transient elastography.